Connect your AI

King Pharmaceuticals KG Derivative Liability

Derivative Liability at other companies

Arch Capital GroupACGL

——

SiriusPointSPNT

——

Reinsurance Group of AmericaRGA

——

Kearny FinancialKRNY

——

Community Financial SystemCBU

——

Other financials

Income statement

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

Operating cash flow-$15.1M-1,628%

Valuation

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

Net margin131.5%—

Returns & leverage

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilities.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's derivative liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is King Pharmaceuticals's derivative liability?: King Pharmaceuticals (KG) reported derivative liability of $3.98M in Q1 2026.